JP2016538855A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538855A5
JP2016538855A5 JP2016532594A JP2016532594A JP2016538855A5 JP 2016538855 A5 JP2016538855 A5 JP 2016538855A5 JP 2016532594 A JP2016532594 A JP 2016532594A JP 2016532594 A JP2016532594 A JP 2016532594A JP 2016538855 A5 JP2016538855 A5 JP 2016538855A5
Authority
JP
Japan
Prior art keywords
car
nucleic acid
acid sequence
spacer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532594A
Other languages
English (en)
Japanese (ja)
Other versions
JP6538684B2 (ja
JP2016538855A (ja
Filing date
Publication date
Priority claimed from GB201320573A external-priority patent/GB201320573D0/en
Priority claimed from GB201410934A external-priority patent/GB201410934D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053452 external-priority patent/WO2015075469A1/en
Publication of JP2016538855A publication Critical patent/JP2016538855A/ja
Publication of JP2016538855A5 publication Critical patent/JP2016538855A5/ja
Application granted granted Critical
Publication of JP6538684B2 publication Critical patent/JP6538684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532594A 2013-11-21 2014-11-21 細胞 Active JP6538684B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201320573A GB201320573D0 (en) 2013-11-21 2013-11-21 T Cell
GB1320573.7 2013-11-21
GB1410934.2 2014-06-19
GB201410934A GB201410934D0 (en) 2014-06-19 2014-06-19 T cell
PCT/GB2014/053452 WO2015075469A1 (en) 2013-11-21 2014-11-21 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018240817A Division JP2019041775A (ja) 2013-11-21 2018-12-25 細胞

Publications (3)

Publication Number Publication Date
JP2016538855A JP2016538855A (ja) 2016-12-15
JP2016538855A5 true JP2016538855A5 (enExample) 2017-10-19
JP6538684B2 JP6538684B2 (ja) 2019-07-03

Family

ID=52003983

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016532594A Active JP6538684B2 (ja) 2013-11-21 2014-11-21 細胞
JP2016532581A Active JP6433498B2 (ja) 2013-11-21 2014-11-21 細胞
JP2018240817A Withdrawn JP2019041775A (ja) 2013-11-21 2018-12-25 細胞
JP2020213272A Pending JP2021045172A (ja) 2013-11-21 2020-12-23 細胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016532581A Active JP6433498B2 (ja) 2013-11-21 2014-11-21 細胞
JP2018240817A Withdrawn JP2019041775A (ja) 2013-11-21 2018-12-25 細胞
JP2020213272A Pending JP2021045172A (ja) 2013-11-21 2020-12-23 細胞

Country Status (19)

Country Link
US (10) US10172886B2 (enExample)
EP (6) EP3858378A1 (enExample)
JP (4) JP6538684B2 (enExample)
KR (2) KR101991555B1 (enExample)
CN (2) CN105792840B (enExample)
AU (2) AU2014351558B2 (enExample)
BR (2) BR112016011460A2 (enExample)
CA (2) CA2929984C (enExample)
CL (2) CL2016001135A1 (enExample)
DK (2) DK3071222T3 (enExample)
ES (2) ES2832586T3 (enExample)
HU (1) HUE051523T2 (enExample)
IL (2) IL245573B (enExample)
MX (2) MX373687B (enExample)
PL (2) PL3071222T3 (enExample)
PT (2) PT3071222T (enExample)
RU (2) RU2732236C2 (enExample)
SG (2) SG11201603484PA (enExample)
WO (3) WO2015075468A1 (enExample)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
ES2832586T3 (es) 2013-11-21 2021-06-10 Autolus Ltd Célula
CA2932424C (en) 2013-12-06 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
WO2015095895A1 (en) 2013-12-20 2015-06-25 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982673B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
KR102508166B1 (ko) 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
US10428305B2 (en) 2014-05-15 2019-10-01 National University Of Singapore Modified natural killer cells that express IL15 and uses thereof
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
ES2959683T3 (es) 2014-07-15 2024-02-27 Juno Therapeutics Inc Células manipuladas para terapia celular adoptiva
GB201415347D0 (en) * 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
EP3233095A2 (en) * 2014-12-17 2017-10-25 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
BR112017013690A2 (pt) 2014-12-24 2018-03-06 Ucl Business Plc célula
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
JP6912386B2 (ja) * 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なIL13Rα2を認識するCAR T細胞
SG10201913124RA (en) 2015-02-06 2020-03-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
KR102632082B1 (ko) * 2015-02-27 2024-02-02 아이셀 진 테라퓨틱스 엘엘씨 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도
CA2981751A1 (en) * 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US11827904B2 (en) * 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US9574014B2 (en) * 2015-05-15 2017-02-21 City Of Hope Chimeric antigen receptor compositions
CN108174607A (zh) * 2015-05-29 2018-06-15 朱诺治疗学股份有限公司 用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP3307876B1 (en) 2015-06-10 2023-09-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
WO2016210293A1 (en) 2015-06-25 2016-12-29 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
MX2018001568A (es) * 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
GB201514874D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Cell
CN108348620A (zh) 2015-09-28 2018-07-31 明尼苏达大学董事会 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
GB201518817D0 (en) * 2015-10-23 2015-12-09 Autolus Ltd Cell
US11207339B2 (en) 2015-10-30 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
KR20180118175A (ko) * 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
US11400116B2 (en) 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
US10222369B2 (en) * 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
JP7114490B2 (ja) * 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
WO2018045325A1 (en) * 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
CN107893052B (zh) * 2016-09-09 2023-11-03 科济生物医药(上海)有限公司 融合蛋白及其应用
EP3519443A4 (en) * 2016-09-30 2020-06-10 Baylor College of Medicine CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
WO2018087557A1 (en) 2016-11-11 2018-05-17 Autolus Limited Chimeric antigen receptor
CN110268049B (zh) 2016-11-22 2024-06-14 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
JP7382829B2 (ja) * 2017-01-10 2023-11-17 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現するt細胞
EP3577134A1 (en) * 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
AU2018246235B2 (en) 2017-03-27 2023-12-21 National University Of Singapore Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy
CN110914289B (zh) * 2017-05-12 2024-05-14 克里斯珀医疗股份公司 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
WO2018211244A1 (en) * 2017-05-15 2018-11-22 Autolus Limited A cell comprising a chimeric antigen receptor (car)
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
SG10202109108UA (en) 2017-06-21 2021-09-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
EP3662055A1 (en) * 2017-08-02 2020-06-10 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP2020535814A (ja) 2017-09-28 2020-12-10 インパクト−バイオ リミテッド 阻害性キメラ抗原受容体(iCAR)を調製するための普遍的プラットフォーム
CN111247168B (zh) * 2017-10-12 2023-12-29 美商生物细胞基因治疗有限公司 靶向多种抗原的复合嵌合抗原受体(cCAR)及其组成和使用方法
EP3700581A4 (en) 2017-10-25 2021-08-18 Actinium Pharmaceuticals, Inc. ANTI-CD45 PACKAGING PROCESSES AND ASSOCIATED USES IN COMBINATION WITH GENETICALLY MODIFIED CELL THERAPIES
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201803079D0 (en) * 2018-02-26 2018-04-11 Autolus Ltd Cell
WO2019177986A1 (en) * 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
WO2019193476A1 (en) 2018-04-02 2019-10-10 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
IL278348B2 (en) 2018-05-11 2025-03-01 Crispr Therapeutics Ag Methods and preparations for treating cancer
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
US11963981B2 (en) 2018-05-15 2024-04-23 Autolus Limited Chimeric antigen receptor
WO2019226945A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
GB201813178D0 (en) 2018-08-13 2018-09-26 Autolus Ltd Cell
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
JP7458382B2 (ja) 2018-09-27 2024-03-29 オートラス リミテッド キメラ抗原受容体
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632460A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3860642A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) * 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
MX2021006968A (es) 2018-12-12 2021-10-13 Kite Pharma Inc Antígeno quimérico y receptores de las células t, y métodos de uso.
ES3051182T3 (en) 2019-01-23 2025-12-26 Miltenyi Biotec Bv & Co Kg A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
MX2021013225A (es) * 2019-05-01 2022-01-06 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8.
CA3140064A1 (en) * 2019-05-16 2020-11-19 University Of Washington Lockr-mediated recruitment of car t cells
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
US20220257757A1 (en) 2019-07-16 2022-08-18 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
GB201910185D0 (en) 2019-07-16 2019-08-28 Autolus Ltd Method
JP2022546315A (ja) * 2019-08-20 2022-11-04 センティ バイオサイエンシズ インコーポレイテッド キメラ抑制性受容体
US20230030702A1 (en) * 2019-09-05 2023-02-02 Migal Galilee Research Institute Ltd Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
US20220401537A1 (en) * 2019-09-16 2022-12-22 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
MX2022003885A (es) * 2019-10-08 2022-07-13 Provincial Health Services Authority Receptores quimericos de citoquinas.
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
WO2021108670A1 (en) * 2019-11-26 2021-06-03 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
IL293716A (en) 2019-12-11 2022-08-01 A2 Biotherapeutics Inc Lilrb1-based chimeric antigen receptor
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN115298209A (zh) * 2020-02-20 2022-11-04 森迪生物科学公司 抑制性嵌合受体构造体
TW202144396A (zh) * 2020-02-20 2021-12-01 美商聖堤生物科技股份有限公司 抑制性嵌合受體架構
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
EP3915578A1 (en) 2020-05-28 2021-12-01 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
CN116490518A (zh) 2020-07-17 2023-07-25 西穆尔克斯股份有限公司 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
EP4058474B1 (en) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
KR102859548B1 (ko) * 2020-08-20 2025-09-12 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
EP4021465A4 (en) * 2020-09-21 2023-02-22 A2 Biotherapeutics, Inc. MANIPULATED IMMUNE CELLS
CN116648260A (zh) * 2020-10-15 2023-08-25 小利兰·斯坦福大学董事会 用于抑制自然杀伤细胞受体的组合物和方法
US20230405047A1 (en) 2020-11-09 2023-12-21 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
MX2023009581A (es) 2021-02-16 2023-08-23 A2 Biotherapeutics Inc Composiciones y metodos para tratar tipos de cancer her2 positivos.
KR20230148837A (ko) 2021-02-25 2023-10-25 라이엘 이뮤노파마, 인크. Ror1 표적화 키메라 항원 수용체
US20240261332A1 (en) * 2021-05-26 2024-08-08 Board Of Regents, The University Of Texas System Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
US20240336903A1 (en) * 2021-08-19 2024-10-10 Shandong Boan Biotechnology Co., Ltd. Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
GB202112923D0 (en) 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
EP4413031A1 (en) 2021-10-06 2024-08-14 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
EP4522204A1 (en) 2022-05-11 2025-03-19 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
GB202209920D0 (en) 2022-07-06 2022-08-17 Autolus Ltd Cell
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
EP4520346A1 (en) 2023-09-06 2025-03-12 Gyncentrum Sp. z o.o. Cells, methods and systems for use in the treatment of a cancer with dual-car-t
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
WO2003046141A2 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP2614077B1 (en) * 2010-09-08 2016-08-17 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
MX386060B (es) * 2013-03-15 2025-03-18 Memorial Sloan Kettering Cancer Center Composiciones y usos para inmunoterapia.
ES2832586T3 (es) 2013-11-21 2021-06-10 Autolus Ltd Célula
KR102508166B1 (ko) * 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell

Similar Documents

Publication Publication Date Title
JP2016538855A5 (enExample)
JP2016538854A5 (enExample)
JP6606210B2 (ja) Mndプロモーターのキメラ抗原受容体
RU2016124280A (ru) Клетка
JP7263235B2 (ja) TGFβシグナルコンバーター
JP2018523484A5 (enExample)
KR102523934B1 (ko) Bcma 키메릭 항원 수용체
US11999773B2 (en) Anti-BCMA chimeric antigen receptors
JP2018532407A5 (enExample)
ES2800906T3 (es) Métodos mejorados para producir terapias celulares adoptivas
JP2017537627A5 (enExample)
JP2018501794A5 (enExample)
JP2017526361A5 (enExample)
JP2019527537A (ja) キメラ抗原受容体と、bcmaに結合するcar−t細胞
JP2018517410A5 (enExample)
JP2017500869A5 (enExample)
TW202023580A (zh) 使用靶特異性融合蛋白進行tcr再程式化之組合物及方法
CN107106670A (zh) 用于修饰的t细胞的方法和组合物
JP2019530431A5 (enExample)
TW202432833A (zh) 新穎cd19結合體、包含彼之car—t構築體及其使用方法
KR20230017778A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-vsig4 조성물 및 방법, 그리고 이의 용도
KR20230025655A (ko) 암 치료용 조성물 및 방법
CN118055944A (zh) 调节Bcl-2增强嵌合抗原受体癌症免疫疗法功效
WO2025213184A1 (en) Novel tcrs and neoantigens in srsf2 and zrsr2 mutated cancers
HK40111221A (zh) 调节bcl-2增强嵌合抗原受体癌症免疫疗法功效